Lymphoma: turning biology into cures

Area of Science:

• Oncology
• Hematology
• Genetics

Background:

• Diffuse large B-cell lymphoma (DLBCL) is the most frequent aggressive non-Hodgkin lymphoma, with around 5,000 UK cases annually.
• The R-CHOP regimen is the current standard of care, achieving approximately 75% cure rates, but has not been surpassed despite extensive research.
• Patients unresponsive to R-CHOP face a poor prognosis, highlighting the need for alternative therapeutic strategies.

Purpose of the Study:

• To explore the molecular heterogeneity of DLBCL.
• To identify novel therapeutic targets through advanced gene expression profiling and mutational analysis.
• To investigate precision medicine approaches for DLBCL treatment.

Main Methods:

• Utilizing gene expression profiling and mutational analysis to understand DLBCL heterogeneity.
• Investigating new therapeutic agents, including small molecule inhibitors.
• Developing novel combination therapies tailored to specific DLBCL subtypes.

Main Results:

• DLBCL exhibits significant molecular heterogeneity.
• Advances in molecular analysis are revealing potential new therapeutic targets.
• Precision medicine strategies are under investigation for DLBCL.

Conclusions:

• Targeting heterogeneous DLBCL subtypes with novel combinations is a promising avenue for progress.
• Precision medicine, guided by diagnostics, offers hope for patients resistant to R-CHOP.
• Personalized treatment paradigms are essential to overcome treatment failures in DLBCL.